pharma · high blood pressure · increased blood clotting
APREMEDA s.r.o
s.r.o.
APREMEDA s.r.o clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- EU
- Founded
- 2020
- Employees
- 18
- Programs
- 5
- Drugs
- 16
- Patents
- 0
APREMEDA s.r.o projects
4 ClinicalTrials.gov programs sponsored by APREMEDA s.r.o.
APREMEDA s.r.o has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
01/2023/Pozlab
s.r.o.
increased blood clotting
1 trial -
204-PKT-202301
s.r.o.
high blood pressure
1 trial -
A pilot for UDCA causes a reduction in chol…
s.r.o.
UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals.
1 trial -
CPA 556-24
s.r.o.
healthy subjects, It is used in conditions with decreased immunity to enhance it e.g. in case of recurrent and chronic viral infections.
1 trial
Frequently asked questions
How many clinical projects does APREMEDA s.r.o have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.